As of Aug 28 2014 4:00PM
Minimum 20 minute delay
  • 8/28/2014 7:00:41 AM

    Covidien Acquires Venous Disease Treatment Developer Sapheon, Inc.

    Transaction expands Covidien’s market leading portfolio with next generation technology for treatment of varicose veins DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 28, 2014-- Covidien plc (NYSE: COV) today announced that it has acquired …
  • 8/26/2014 8:02:48 AM

    Announcement under Irish Takeover Rules Relevant Securities in Issue – August 26, 2014

    DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 26, 2014-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on August 25, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 451,825,023 ordinary shares, par value …
  • 8/22/2014 7:00:13 AM

    Covidien Acquires Reverse Medical Corporation

    Generates Opportunity to Leverage Existing Vascular Technologies and Customer Relationships to Drive Increased Market Penetration DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 22, 2014-- Covidien plc (NYSE:COV) today announced it has acquired …

A Partner in Health

Collaborating with physicians and other healthcare professionals, focusing on research and development and maintaining clinical leadership add up to innovative medical solutions that make a difference.

Conscientious Collaboration

Ensuring ethical interactions with healthcare professionals is vital to the global healthcare environment. Covidien’s Conscientious Collaboration platform is our commitment to open communications about the need to ensure compliant interactions with our customers and partners.

One Covidien

One look. One Covidien. Experience the new unified look of Covidien. Easy-to-use labeling. New outside packaging with the same quality products inside. First-class service and support.

Visit Us